Acceleron Pharma Inc.
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
58
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Jan 23 to 25, 2027 · next Jan 23
- 1 fee due Feb 13, 2027The maintenance fee for Isolated GDF Trap Polypeptide (US 10,377,996) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 4 fees due May 7 to 28, 2027 · next May 7
- 1 fee due Jun 10, 2027The maintenance fee for ALK7 Binding Proteins and Uses Thereof (US 10,501,547) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Compositions and methods for treating spinal muscular atrophy (US 11,857,599) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Methods for treating vascular eye disorders with actrii antagonists (US 10,550,170) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for ActRIIa and ALK4 polypeptides for treating kidney fibrosis, inflammation and injury (US 11,976,111) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,951,771 | Activin-Actriia Antagonists and Uses for Promoting Bone Growth In force · Medium confidence | In force | Medium confidence | |
| US 8,067,360 | A Method for Promoting Bone Growth Using Activin-Actriia Antagonists In force · Medium confidence | In force | Medium confidence | |
| US 8,128,933 | Method of promoting bone growth by an anti-activin B antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 8,486,403 | Method of promoting bone growth by an anti-activin A antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 8,629,109 | Method for Promoting Bone Growth Using Activin-Actriia Antagonists In force · Low confidence | In force | Low confidence | |
| US 9,163,075 | AN ISOLATED POLYNUCLEOTIDE THAT ENCODES AN ActRIIa-Fc FUSION POLYPEPTIDE In force · Medium confidence | In force | Medium confidence | |
| US 9,480,742 | Method of promoting bone growth by an anti-actriia antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 10,071,135 | A Method of Identifying an Agent That Promotes Bone Growth or Increases Bone Density In force · Medium confidence | In force | Medium confidence | |
| US 10,239,940 | Method of Promoting Bone Growth by an Anti-Actriia Antibody In force · Medium confidence | In force | Medium confidence | |
| US 11,129,873 | Method for Promoting Bone Growth Using Activin-Actriia Antagonists In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 135: 15 patents in force now held by others · 8 lapsed for an unpaid fee · 16 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
25 pending · 36 abandoned · 85 no status recorded